What Is CJC-1295?

CJC-1295 is a 30-amino-acid peptide that mimics the action of natural GHRH (growth hormone-releasing hormone). It was developed to overcome the primary limitation of native GHRH: an extremely short half-life of just 7 minutes in the bloodstream.

CJC-1295 exists in two variants:

• CJC-1295 with DAC: The Drug Affinity Complex allows the peptide to bind to albumin in the blood, extending its half-life to approximately 6–8 days. This produces sustained, elevated GH levels.
• CJC-1295 without DAC (Modified GRF 1-29): Has a half-life of approximately 30 minutes, producing a shorter but more natural GH pulse. This is the more commonly used research variant.

Most researchers prefer the no-DAC version because it better mimics the body's natural pulsatile GH release pattern.

CJC-1295 works through the GHRH receptor pathway — distinct from ghrelin-based secretagogues like ipamorelin:

• GHRH receptor binding: CJC-1295 binds to GHRH receptors on pituitary somatotroph cells, stimulating GH synthesis and release
• Amplified GH pulses: Rather than creating new GH pulses, CJC-1295 amplifies the amplitude of existing natural pulses
• IGF-1 elevation: Sustained GH elevation drives hepatic IGF-1 production, mediating downstream anabolic and recovery effects
• Synergy with GHSPs: CJC-1295 works on a different receptor than ipamorelin/GHRP peptides, making combination protocols highly effective

By amplifying rather than replacing natural GH signaling, CJC-1295 maintains physiological feedback mechanisms — a significant advantage over exogenous HGH.

Research into CJC-1295 has identified several promising benefits:

• Sustained GH and IGF-1 elevation: Studies show 2–10x increases in GH levels lasting days (with DAC) or hours (without DAC)
• Improved body composition: Enhanced lipolysis and lean mass preservation through elevated GH/IGF-1
• Deep sleep enhancement: GHRH analogs are closely linked to slow-wave (deep) sleep promotion
• Recovery acceleration: Elevated IGF-1 supports connective tissue repair, collagen synthesis, and bone healing
• Anti-aging effects: Restoring youthful GH levels may improve skin elasticity, cognitive function, and metabolic health

Dosing differs significantly between the two CJC-1295 variants:

CJC-1295 Without DAC (Modified GRF 1-29)

• Dose: 100–200 mcg per injection
• Frequency: 2–3 times daily (morning, post-workout, before bed)
• Often paired with: Ipamorelin at 200–300 mcg per injection for synergistic GH release

CJC-1295 With DAC

• Dose: 2 mg per injection
• Frequency: Once or twice per week due to extended half-life

Reconstitution: Reconstitute with bacteriostatic water. Refrigerate and use within 3–4 weeks.

These dosages are drawn from research literature. Work with a qualified provider for individualized protocols.

CJC-1295 is generally well-tolerated, with side effects related to elevated GH levels:

• Water retention: Mild fluid retention, especially during the first few weeks
• Tingling and numbness: Paresthesia in extremities from GH elevation
• Flushing: Warmth or flushing sensation shortly after injection
• Fatigue or drowsiness: Particularly with evening doses, which may actually be beneficial for sleep
• Headache: Occasionally reported, typically mild and transient

The DAC version carries a higher side effect risk due to sustained GH elevation, which can lead to more pronounced water retention and potential GH-related issues. CJC-1295 is banned by WADA.

For reliable research results, sourcing high-purity CJC-1295 is critical. We recommend Ascension Peptides:

• 99%+ purity verified by independent HPLC analysis
• Both variants available — with and without DAC
• Batch-specific COAs published for full transparency
• US-based shipping with temperature-controlled packaging

Ascension Peptides is a DailyVial affiliate partner known for consistent quality and transparent testing practices.